Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Head and Neck Cancer

  Free Subscription


Articles published in Radiother Oncol

Retrieve available abstracts of 100 articles:
HTML format
Text format



Single Articles


    November 2017
  1. LEE AW, Ng WT, Pan JJ, Poh SS, et al
    International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma.
    Radiother Oncol. 2017 Nov 15. pii: S0167-8140(17)32686.
    PubMed     Text format     Abstract available


  2. BOGOWICZ M, Leijenaar RTH, Tanadini-Lang S, Riesterer O, et al
    Post-radiochemotherapy PET radiomics in head and neck cancer - The influence of radiomics implementation on the reproducibility of local control tumor models.
    Radiother Oncol. 2017 Nov 6. pii: S0167-8140(17)32663.
    PubMed     Text format     Abstract available


  3. TAKAHASHI N, Umezawa R, Takanami K, Yamamoto T, et al
    Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017 Nov 3. pii: S0167-8140(17)32659.
    PubMed     Text format     Abstract available


    October 2017
  4. CEREDA E, Cappello S, Colombo S, Klersy C, et al
    Nutritional counseling with or without systematic use of oral nutritional supplements in head and neck cancer patients undergoing radiotherapy.
    Radiother Oncol. 2017 Oct 27. pii: S0167-8140(17)32655.
    PubMed     Text format     Abstract available


  5. OU D, Garberis I, Adam J, Blanchard P, et al
    Prognostic value of tissue necrosis, hypoxia-related markers and correlation with HPV status in head and neck cancer patients treated with bio- or chemo-radiotherapy.
    Radiother Oncol. 2017 Oct 24. pii: S0167-8140(17)32647.
    PubMed     Text format     Abstract available


  6. DE-COLLE C, Menegakis A, Monnich D, Welz S, et al
    SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy.
    Radiother Oncol. 2017 Oct 20. pii: S0167-8140(17)32648.
    PubMed     Text format     Abstract available


  7. RAO AD, Coquia S, De Jong R, Gourin C, et al
    Effects of biodegradable hydrogel spacer injection on contralateral submandibular gland sparing in radiotherapy for head and neck cancers.
    Radiother Oncol. 2017 Oct 3. pii: S0167-8140(17)32584.
    PubMed     Text format     Abstract available


    September 2017
  8. MICHIELS S, Barragan AM, Souris K, Poels K, et al
    Patient-specific bolus for range shifter air gap reduction in intensity-modulated proton therapy of head-and-neck cancer studied with Monte Carlo based plan optimization.
    Radiother Oncol. 2017 Sep 23. pii: S0167-8140(17)32568.
    PubMed     Text format     Abstract available


  9. WOPKEN K, Bijl HP, Langendijk JA
    Prognostic factors for tube feeding dependence after curative (chemo-) radiation in head and neck cancer: A systematic review of literature.
    Radiother Oncol. 2017 Sep 21. pii: S0167-8140(17)32545.
    PubMed     Text format     Abstract available


  10. CHANG CL, Tsai HC, Lin WC, Chang JH, et al
    Dose escalation intensity-modulated radiotherapy-based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma.
    Radiother Oncol. 2017 Sep 15. pii: S0167-8140(17)32548.
    PubMed     Text format     Abstract available


  11. SHIRAISHI Y, Xu C, Yang J, Komaki R, et al
    Dosimetric comparison to the heart and cardiac substructure in a large cohort of esophageal cancer patients treated with proton beam therapy or Intensity-modulated radiation therapy.
    Radiother Oncol. 2017 Sep 13. pii: S0167-8140(17)32550.
    PubMed     Text format     Abstract available


    August 2017
  12. YANG H, Chen X, Lin S, Rong J, et al
    Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
    Radiother Oncol. 2017 Aug 29. pii: S0167-8140(17)32479.
    PubMed     Text format     Abstract available


  13. LOCK S, Perrin R, Seidlitz A, Bandurska-Luque A, et al
    Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
    Radiother Oncol. 2017 Aug 23. pii: S0167-8140(17)32517.
    PubMed     Text format     Abstract available


  14. FERRIS MJ, Zhong J, Switchenko JM, Higgins KA, et al
    Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy.
    Radiother Oncol. 2017 Aug 18. pii: S0167-8140(17)32515.
    PubMed     Text format     Abstract available


  15. TONLAAR N, Galoforo S, Thibodeau BJ, Ahmed S, et al
    Antitumor activity of the dual PI3K/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer.
    Radiother Oncol. 2017 Aug 16. pii: S0167-8140(17)32501.
    PubMed     Text format     Abstract available


  16. HAWKINS PG, Lee JY, Mao Y, Li P, et al
    Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life.
    Radiother Oncol. 2017 Aug 16. pii: S0167-8140(17)32502.
    PubMed     Text format     Abstract available


  17. HUIZING FJ, Hoeben BAW, Franssen G, Lok J, et al
    Preclinical validation of 111In-girentuximab-F(ab')2 as a tracer to image hypoxia related marker CAIX expression in head and neck cancer xenografts.
    Radiother Oncol. 2017 Aug 5. pii: S0167-8140(17)32484.
    PubMed     Text format     Abstract available


    July 2017
  18. MOHAMED ASR, Cardenas CE, Garden AS, Awan MJ, et al
    Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.
    Radiother Oncol. 2017 Jul 31. pii: S0167-8140(17)32476.
    PubMed     Text format     Abstract available


  19. ZHAI TT, van Dijk LV, Huang BT, Lin ZX, et al
    Improving the prediction of overall survival for head and neck cancer patients using image biomarkers in combination with clinical parameters.
    Radiother Oncol. 2017 Jul 29. pii: S0167-8140(17)32472.
    PubMed     Text format     Abstract available


  20. NEVENS D, Duprez F, Bonte K, Deron P, et al
    Upfront vs. no upfront neck dissection in primary head and neck cancer radio(chemo)therapy: Tumor control and late toxicity.
    Radiother Oncol. 2017 Jul 26. pii: S0167-8140(17)32470.
    PubMed     Text format     Abstract available


  21. NEVENS D, Duprez F, Daisne JF, De Neve W, et al
    Dose de-escalation to the elective lymph nodes in head and neck cancer. Reply to Amdur et al.
    Radiother Oncol. 2017 Jul 24. pii: S0167-8140(17)32456.
    PubMed     Text format    


  22. RASSAMEGEVANON T, Lock S, Range U, Krause M, et al
    Tumor heterogeneity determined with a gammaH2AX foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models.
    Radiother Oncol. 2017 Jul 21. pii: S0167-8140(17)32447.
    PubMed     Text format     Abstract available


  23. XI M, Xu C, Liao Z, Hofstetter WL, et al
    The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy.
    Radiother Oncol. 2017 Jul 4. pii: S0167-8140(17)30428.
    PubMed     Text format     Abstract available


    June 2017
  24. ZHANG D, Zhang W, Liu W, Mao Y, et al
    Human papillomavirus infection increases the chemoradiation response of esophageal squamous cell carcinoma based on P53 mutation.
    Radiother Oncol. 2017 Jun 21. pii: S0167-8140(17)30408.
    PubMed     Text format     Abstract available


  25. MCLAY M, Stedford A, Yurkowski E, Matlock S, et al
    Population-based assessment of relationship between volume of practice and outcomes in head and neck cancer patients treated in a provincially coordinated radiotherapy program.
    Radiother Oncol. 2017 Jun 15. pii: S0167-8140(17)30401.
    PubMed     Text format     Abstract available


    May 2017
  26. KOPPENHAGEN P, Dickreuter E, Cordes N
    Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
    Radiother Oncol. 2017 May 31. pii: S0167-8140(17)30375.
    PubMed     Text format     Abstract available


  27. CHEN J, Cai W, Zheng X, Chen Y, et al
    The pattern of cervical lymph node metastasis in thoracic esophageal squamous cell carcinoma may affect the target decision for definitive radiotherapy.
    Radiother Oncol. 2017 May 24. pii: S0167-8140(17)30152.
    PubMed     Text format     Abstract available


  28. LAI TY, Wang TH, Liu CJ, Chao TF, et al
    Risk factors for osteonecrosis of the jaw in oral cancer patients after surgery and eventual adjuvant treatment: The potential role of chemotherapy.
    Radiother Oncol. 2017 May 19. pii: S0167-8140(17)30362.
    PubMed     Text format     Abstract available


  29. FAN CY, Lin CS, Chao HL, Huang WY, et al
    Risk of hypothyroidism among patients with nasopharyngeal carcinoma treated with radiation therapy: A Population-Based Cohort Study.
    Radiother Oncol. 2017 May 19. pii: S0167-8140(17)30367.
    PubMed     Text format     Abstract available


  30. CHRISTIAENS M, Collette S, Overgaard J, Gregoire V, et al
    Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure.
    Radiother Oncol. 2017 May 4. pii: S0167-8140(17)30160.
    PubMed     Text format     Abstract available


    April 2017
  31. LIN SH, Merrell KW, Shen J, Verma V, et al
    Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer.
    Radiother Oncol. 2017 Apr 25. pii: S0167-8140(17)30154.
    PubMed     Text format     Abstract available


  32. WELZ S, Monnich D, Pfannenberg C, Nikolaou K, et al
    Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial.
    Radiother Oncol. 2017 Apr 20. pii: S0167-8140(17)30144.
    PubMed     Text format     Abstract available


  33. RUSTHOVEN CG, Lanning RM, Jones BL, Amini A, et al
    Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy.
    Radiother Oncol. 2017 Apr 19. pii: S0167-8140(17)30130.
    PubMed     Text format     Abstract available


  34. ZHU H, Song H, Chen G, Yang X, et al
    eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma.
    Radiother Oncol. 2017 Apr 18. pii: S0167-8140(17)30140.
    PubMed     Text format     Abstract available


  35. YAMASHITA H, Abe O, Nakagawa K
    Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of 18FDG-PET scans: A long follow-up results of phase II study.
    Radiother Oncol. 2017 Apr 17. pii: S0167-8140(17)30141.
    PubMed     Text format    


  36. WU B, Kusters M, Kunze-Busch M, Dijkema T, et al
    Cross-institutional knowledge-based planning (KBP) implementation and its performance comparison to Auto-Planning Engine (APE).
    Radiother Oncol. 2017;123:57-62.
    PubMed     Text format     Abstract available


    March 2017
  37. NEVENS D, Duprez F, Daisne JF, Schatteman J, et al
    Recurrence patterns after a decreased dose of 40Gy to the elective treated neck in head and neck cancer.
    Radiother Oncol. 2017 Mar 22. pii: S0167-8140(17)30099.
    PubMed     Text format     Abstract available


  38. LIGTENBERG H, Jager EA, Caldas-Magalhaes J, Schakel T, et al
    Modality-specific target definition for laryngeal and hypopharyngeal cancer on FDG-PET, CT and MRI.
    Radiother Oncol. 2017 Mar 1. pii: S0167-8140(17)30064.
    PubMed     Text format     Abstract available


  39. NAKAMURA N, Zenda S, Tahara M, Okano S, et al
    Proton beam therapy for olfactory neuroblastoma.
    Radiother Oncol. 2017;122:368-372.
    PubMed     Text format     Abstract available


    February 2017
  40. ZSCHAECK S, Lock S, Leger S, Haase R, et al
    FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy.
    Radiother Oncol. 2017 Feb 17. pii: S0167-8140(17)30047.
    PubMed     Text format     Abstract available


  41. BERTHON B, Evans M, Marshall C, Palaniappan N, et al
    Head and neck target delineation using a novel PET automatic segmentation algorithm.
    Radiother Oncol. 2017;122:242-247.
    PubMed     Text format     Abstract available


  42. VAN LOON J, Even AJ, Aerts HJ, Ollers M, et al
    PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer.
    Radiother Oncol. 2017;122:267-273.
    PubMed     Text format     Abstract available


  43. BUSCH CJ, Kroger MS, Jensen J, Kriegs M, et al
    G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1.
    Radiother Oncol. 2017;122:260-266.
    PubMed     Text format     Abstract available


  44. KOVACS G, Martinez-Monge R, Budrukkar A, Guinot JL, et al
    GEC-ESTRO ACROP recommendations for head & neck brachytherapy in squamous cell carcinomas: 1st update - Improvement by cross sectional imaging based treatment planning and stepping source technology.
    Radiother Oncol. 2017;122:248-254.
    PubMed     Text format     Abstract available


  45. HAMMING-VRIEZE O, van Kranen SR, Heemsbergen WD, Lange CA, et al
    Analysis of GTV reduction during radiotherapy for oropharyngeal cancer: Implications for adaptive radiotherapy.
    Radiother Oncol. 2017;122:224-228.
    PubMed     Text format     Abstract available


  46. GRONLUND E, Johansson S, Montelius A, Ahnesjo A, et al
    Dose painting by numbers based on retrospectively determined recurrence probabilities.
    Radiother Oncol. 2017;122:236-241.
    PubMed     Text format     Abstract available


  47. SODERSTROM K, Nilsson P, Laurell G, Zackrisson B, et al
    Dysphagia - Results from multivariable predictive modelling on aspiration from a subset of the ARTSCAN trial.
    Radiother Oncol. 2017;122:192-199.
    PubMed     Text format     Abstract available


  48. NEVENS D, Duprez F, Daisne JF, Laenen A, et al
    Radiotherapy induced dermatitis is a strong predictor for late fibrosis in head and neck cancer. The development of a predictive model for late fibrosis.
    Radiother Oncol. 2017;122:212-216.
    PubMed     Text format     Abstract available


  49. VAN DIJK LV, Brouwer CL, van der Schaaf A, Burgerhof JG, et al
    CT image biomarkers to improve patient-specific prediction of radiation-induced xerostomia and sticky saliva.
    Radiother Oncol. 2017;122:185-191.
    PubMed     Text format     Abstract available


    January 2017
  50. PATEL R, Barker HE, Kyula J, McLaughlin M, et al
    An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation.
    Radiother Oncol. 2017 Jan 25. pii: S0167-8140(16)34478.
    PubMed     Text format     Abstract available


  51. FUCCIO L, Mandolesi D, Farioli A, Hassan C, et al
    Brachytherapy for the palliation of dysphagia owing to esophageal cancer: A systematic review and meta-analysis of prospective studies.
    Radiother Oncol. 2017 Jan 16. pii: S0167-8140(17)30003.
    PubMed     Text format     Abstract available


    November 2016
  52. THOR M, Owosho AA, Clark HD, Oh JH, et al
    Internal and external generalizability of temporal dose-response relationships for xerostomia following IMRT for head and neck cancer.
    Radiother Oncol. 2016 Nov 24. pii: S0167-8140(16)34380.
    PubMed     Text format     Abstract available


  53. LESZCZYNSKA KB, Dobrynin G, Leslie RE, Ient J, et al
    Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer.
    Radiother Oncol. 2016 Nov 10. pii: S0167-8140(16)34372.
    PubMed     Text format     Abstract available


  54. WANG L, Liu L, Han C, Liu S, et al
    The diffusion-weighted magnetic resonance imaging (DWI) predicts the early response of esophageal squamous cell carcinoma to concurrent chemoradiotherapy.
    Radiother Oncol. 2016 Nov 9. pii: S0167-8140(16)34370.
    PubMed     Text format     Abstract available


    October 2016
  55. QIU B, Wang D, Yang H, Xie W, et al
    Combined modalities of magnetic resonance imaging, endoscopy and computed tomography in the evaluation of tumor responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma.
    Radiother Oncol. 2016 Oct 25. pii: S0167-8140(16)34352.
    PubMed     Text format     Abstract available


  56. MARTINEZ-FERNANDEZ MI, Alcalde J, Cambeiro M, Peydro GV, et al
    Perioperative high dose rate brachytherapy (PHDRB) in previously irradiated head and neck cancer: Results of a phase I/II reirradiation study.
    Radiother Oncol. 2016 Oct 13. pii: S0167-8140(16)34287.
    PubMed     Text format     Abstract available


    August 2016
  57. HE L, Chapple A, Liao Z, Komaki R, et al
    Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer.
    Radiother Oncol. 2016 Aug 22. pii: S0167-8140(16)31243.
    PubMed     Text format     Abstract available


  58. NEVENS D, Duprez F, Daisne JF, Dok R, et al
    Reduction of the dose of radiotherapy to the elective neck in head and neck squamous cell carcinoma; a randomized clinical trial. Effect on late toxicity and tumor control.
    Radiother Oncol. 2016 Aug 12. pii: S0167-8140(16)34247.
    PubMed     Text format     Abstract available


  59. CHUTER R, Prestwich R, Bird D, Scarsbrook A, et al
    The use of deformable image registration to integrate diagnostic MRI into the radiotherapy planning pathway for head and neck cancer.
    Radiother Oncol. 2016 Aug 3. pii: S0167-8140(16)31212.
    PubMed     Text format     Abstract available


    July 2016
  60. LOIMU V, Seppala T, Kapanen M, Tuomikoski L, et al
    Diffusion-weighted magnetic resonance imaging for evaluation of salivary gland function in head and neck cancer patients treated with intensity-modulated radiotherapy.
    Radiother Oncol. 2016 Jul 27. pii: S0167-8140(16)31200.
    PubMed     Text format     Abstract available


  61. WONG KH, Kuciejewska A, Sharabiani MT, Ng-Cheng-Hin B, et al
    A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer.
    Radiother Oncol. 2016 Jul 5. pii: S0167-8140(16)31174.
    PubMed     Text format     Abstract available


    June 2016
  62. BROUWER CL, Steenbakkers RJ, van der Schaaf A, Sopacua CT, et al
    Selection of head and neck cancer patients for adaptive radiotherapy to decrease xerostomia.
    Radiother Oncol. 2016 Jun 23. pii: S0167-8140(16)31149.
    PubMed     Text format     Abstract available


  63. LIN P, Min M, Lee M, Holloway L, et al
    Prognostic utility of 18F-FDG PET-CT performed prior to and during primary radiotherapy for nasopharyngeal carcinoma: Index node is a useful prognostic imaging biomarker site.
    Radiother Oncol. 2016 Jun 16. pii: S0167-8140(16)31124.
    PubMed     Text format     Abstract available


  64. MATUSCHEK C, Bolke E, Geigis C, Kammers K, et al
    Influence of dosimetric and clinical criteria on the requirement of artificial nutrition during radiotherapy of head and neck cancer patients.
    Radiother Oncol. 2016 Jun 10. pii: S0167-8140(16)31120.
    PubMed     Text format     Abstract available


    May 2016
  65. CHEN CY, Li CC, Chien CR
    Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis.
    Radiother Oncol. 2016 May 17. pii: S0167-8140(16)31089.
    PubMed     Text format     Abstract available


  66. KJAER T, Dalton SO, Andersen E, Karlsen R, et al
    A controlled study of use of patient-reported outcomes to improve assessment of late effects after treatment for head-and-neck cancer.
    Radiother Oncol. 2016 May 10. pii: S0167-8140(16)31080.
    PubMed     Text format     Abstract available


  67. JANSSENS GO, Langendijk JA, Terhaard CH, Doornaert PA, et al
    Quality-of-life after radiotherapy for advanced laryngeal cancer: Results of a phase III trial of the Dutch Head and Neck Society.
    Radiother Oncol. 2016 May 7. pii: S0167-8140(16)00111.
    PubMed     Text format     Abstract available


    April 2016
  68. TOL JP, Doornaert P, Witte BI, Dahele M, et al
    A longitudinal evaluation of improvements in radiotherapy treatment plan quality for head and neck cancer patients.
    Radiother Oncol. 2016 Apr 26. pii: S0167-8140(16)31045.
    PubMed     Text format     Abstract available


  69. MOSLEMI D, Nokhandani AM, Otaghsaraei MT, Moghadamnia Y, et al
    Management of chemo/radiation-induced oral mucositis in patients with head and neck cancer: A review of the current literature.
    Radiother Oncol. 2016 Apr 21. pii: S0167-8140(16)31035.
    PubMed     Text format     Abstract available


  70. WANG JZ, Li JB, Qi HP, Li YK, et al
    Effect of contrast enhancement in delineating GTV and constructing IGTV of thoracic oesophageal cancer based on 4D-CT scans.
    Radiother Oncol. 2016;119:172-8.
    PubMed     Text format     Abstract available


  71. DEAN JA, Welsh LC, McQuaid D, Wong KH, et al
    Assessment of fully-automated atlas-based segmentation of novel oral mucosal surface organ-at-risk.
    Radiother Oncol. 2016;119:166-71.
    PubMed     Text format     Abstract available


  72. PALMA B, Bazalova-Carter M, Hardemark B, Hynning E, et al
    Assessment of the quality of very high-energy electron radiotherapy planning.
    Radiother Oncol. 2016;119:154-8.
    PubMed     Text format     Abstract available


  73. TAKANAMI K, Arai A, Umezawa R, Takeuchi T, et al
    Association between radiation dose to the heart and myocardial fatty acid metabolic impairment due to chemoradiation-therapy: Prospective study using I-123 BMIPP SPECT/CT.
    Radiother Oncol. 2016;119:77-83.
    PubMed     Text format     Abstract available


    March 2016
  74. MACFARLANE M, Hoover DA, Wong E, Read N, et al
    Evaluation of unified intensity-modulated arc therapy for the radiotherapy of head-and-neck cancer.
    Radiother Oncol. 2016 Mar 31. pii: S0167-8140(16)31017.
    PubMed     Text format     Abstract available


  75. ELICIN O, Nisa L, Dal Pra A, Bojaxhiu B, et al
    Up-front neck dissection followed by definitive (chemo)-radiotherapy in head and neck squamous cell carcinoma: Rationale, complications, toxicity rates, and oncological outcomes - A systematic review.
    Radiother Oncol. 2016 Mar 17. pii: S0167-8140(16)00125.
    PubMed     Text format     Abstract available


  76. RASMUSSEN JH, Hakansson K, Vogelius IR, Aznar MC, et al
    Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer.
    Radiother Oncol. 2016 Mar 15. pii: S0167-8140(16)00127.
    PubMed     Text format     Abstract available


  77. JIN P, Hulshof MC, de Jong R, van Hooft JE, et al
    Quantification of respiration-induced esophageal tumor motion using fiducial markers and four-dimensional computed tomography.
    Radiother Oncol. 2016;118:492-7.
    PubMed     Text format     Abstract available


  78. JANSSENS G, Smeets J, Vander Stappen F, Prieels D, et al
    Sensitivity study of prompt gamma imaging of scanned beam proton therapy in heterogeneous anatomies.
    Radiother Oncol. 2016;118:562-7.
    PubMed     Text format     Abstract available


    February 2016
  79. CHENG Q, Roelofs E, Ramaekers BL, Eekers D, et al
    Development and evaluation of an online three-level proton vs photon decision support prototype for head and neck cancer - Comparison of dose, toxicity and cost-effectiveness.
    Radiother Oncol. 2016 Feb 26. pii: S0167-8140(16)00031.
    PubMed     Text format     Abstract available


  80. HONG A, Zhang X, Jones D, Veillard AS, et al
    Relationships between p53 mutation, HPV status and outcome in oropharyngeal squamous cell carcinoma.
    Radiother Oncol. 2016;118:342-9.
    PubMed     Text format     Abstract available



  81. Beyond mean pharyngeal constrictor dose for beam path toxicity in non-target swallowing muscles: Dose-volume correlates of chronic radiation-associated dysphagia (RAD) after oropharyngeal intensity modulated radiotherapy.
    Radiother Oncol. 2016;118:304-14.
    PubMed     Text format     Abstract available


  82. LYHNE NM, Johansen J, Kristensen CA, Andersen E, et al
    Pattern of failure in 5001 patients treated for glottic squamous cell carcinoma with curative intent - A population based study from the DAHANCA group.
    Radiother Oncol. 2016;118:257-66.
    PubMed     Text format     Abstract available


  83. ROMESSER PB, Cahlon O, Scher E, Zhou Y, et al
    Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation.
    Radiother Oncol. 2016;118:286-92.
    PubMed     Text format     Abstract available


  84. RICHTER C, Pausch G, Barczyk S, Priegnitz M, et al
    First clinical application of a prompt gamma based in vivo proton range verification system.
    Radiother Oncol. 2016;118:232-7.
    PubMed     Text format     Abstract available


  85. GUJRAL DM, Shah BN, Chahal NS, Bhattacharyya S, et al
    Carotid intima-medial thickness as a marker of radiation-induced carotid atherosclerosis.
    Radiother Oncol. 2016;118:323-9.
    PubMed     Text format     Abstract available


  86. LEE JY, Sun JM, Oh DR, Lim SH, et al
    Comparison of weekly versus triweekly cisplatin delivered concurrently with radiation therapy in patients with locally advanced nasopharyngeal cancer: A multicenter randomized phase II trial (KCSG-HN10-02).
    Radiother Oncol. 2016;118:244-50.
    PubMed     Text format     Abstract available


  87. ZENDA S, Akimoto T, Mizumoto M, Hayashi R, et al
    Phase II study of proton beam therapy as a nonsurgical approach for mucosal melanoma of the nasal cavity or para-nasal sinuses.
    Radiother Oncol. 2016;118:267-71.
    PubMed     Text format     Abstract available


  88. JENSEN AD, Poulakis M, Nikoghosyan AV, Welzel T, et al
    High-LET radiotherapy for adenoid cystic carcinoma of the head and neck: 15 years' experience with raster-scanned carbon ion therapy.
    Radiother Oncol. 2016;118:272-80.
    PubMed     Text format     Abstract available


    January 2016
  89. MESSER JA, Mohamed AS, Hutcheson KA, Ding Y, et al
    Magnetic resonance imaging of swallowing-related structures in nasopharyngeal carcinoma patients receiving IMRT: Longitudinal dose-response characterization of quantitative signal kinetics.
    Radiother Oncol. 2016 Jan 28. pii: S0167-8140(16)00033.
    PubMed     Text format     Abstract available


  90. NYQVIST J, Fransson P, Laurell G, Hammerlid E, et al
    Differences in health related quality of life in the randomised ARTSCAN study; accelerated vs. conventional radiotherapy for head and neck cancer. A five year follow up.
    Radiother Oncol. 2016 Jan 6. pii: S0167-8140(15)00685.
    PubMed     Text format     Abstract available


  91. DONOHOE CL, Reynolds JV
    Letter to the Co-Editors-in-Chief, Radiotherapy and Oncology.
    Radiother Oncol. 2016;118:215.
    PubMed     Text format    


    December 2015
  92. KHAN Z, Khan AA, Prasad GB, Khan N, et al
    Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
    Radiother Oncol. 2015 Dec 30. pii: S0167-8140(15)00665.
    PubMed     Text format     Abstract available


  93. DE FELICE F, Musio D, Tombolini V
    Mastication structures definition in head and neck cancer.
    Radiother Oncol. 2015 Dec 29. pii: S0167-8140(15)00677.
    PubMed     Text format    


  94. TAWK B, Schwager C, Deffaa O, Dyckhoff G, et al
    Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma.
    Radiother Oncol. 2015 Dec 19. pii: S0167-8140(15)00647.
    PubMed     Text format     Abstract available


  95. CHRISTIANEN ME, van der Schaaf A, van der Laan HP, Verdonck-de Leeuw IM, et al
    Swallowing sparing intensity modulated radiotherapy (SW-IMRT) in head and neck cancer: Clinical validation according to the model-based approach.
    Radiother Oncol. 2015 Dec 14. pii: S0167-8140(15)00613.
    PubMed     Text format     Abstract available


    November 2015
  96. MOON H, Roh JL, Lee SW, Kim SB, et al
    Prognostic value of nutritional and hematologic markers in head and neck squamous cell carcinoma treated by chemoradiotherapy.
    Radiother Oncol. 2015 Nov 30. pii: S0167-8140(15)00597.
    PubMed     Text format     Abstract available


  97. BUDACH W, Bolke E, Kammers K, Gerber PA, et al
    Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials.
    Radiother Oncol. 2015 Nov 14. pii: S0167-8140(15)00563.
    PubMed     Text format     Abstract available


    July 2015
  98. HUANG W, Huang Y, Sun J, Liu X, et al
    Atlas of the thoracic lymph nodal delineation and recommendations for lymph nodal CTV of esophageal squamous cell cancer in radiation therapy from China.
    Radiother Oncol. 2015;116:100-6.
    PubMed     Text format     Abstract available


  99. SAMUELS SE, Vainshtein J, Spector ME, Ibrahim M, et al
    Impact of retropharyngeal adenopathy on distant control and survival in HPV-related oropharyngeal cancer treated with chemoradiotherapy.
    Radiother Oncol. 2015;116:75-81.
    PubMed     Text format     Abstract available


  100. KLAASSEN R, Bennink RJ, van Tienhoven G, Bijlsma MF, et al
    Feasibility and repeatability of PET with the hypoxia tracer [(18)F]HX4 in oesophageal and pancreatic cancer.
    Radiother Oncol. 2015;116:94-9.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: